The USA-based Institute for Clinical and Economic Review (ICER), England’s National Institute for Health and Care Excellence (NICE), and Canada’s Drug Agency (CDA-AMC) have formed the Health Economics Methods Advisory (HEMA) initiative. The goal of HEMA is to critically and independently research some of the most pressing topics in global health economics and health technology assessment (HTA) methods.
The HEMA initiative brings together an independent working group comprised of research experts, academics, and methodologists in health economics HTA that have both theoretical and practical experience in supporting HTA. The HEMA working group will examine issues that are expected to include topics that are related to health economic methods. HEMA’s selection and prioritization of topics will be guided by a separate steering committee, with representation from the patient, payer, and life sciences communities across all three countries.
The ICER’s chief scientific officer and director of health technology assessment methods and engagement, Dan Ollendorf, stated: “Through this international collaboration, we are looking forward to examining the benefits and disadvantages of new methods in health economics and HTA. There is a need for independent research that can not only critically examine these topics but also assess their feasibility and practicality in HTA settings.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze